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Objectives This study sought to determine the prognostic implications of high platelet reactivity (HPR) assessed in type 2
diabetes mellitus (T2DM) patients while in their steady-state phase of dual antiplatelet therapy.
Background Type 2 diabetes mellitus patients have increased platelet reactivity compared with nondiabetic patients.
Whether HPR assessed in T2DM while in their steady-state phase of dual antiplatelet therapy is associated with
an increased risk of major adverse cardiovascular events (MACE) is unknown.
Methods Platelet function analyses, which included measures of platelet aggregation and activation, were performed in
173 T2DM patients with coronary artery disease on chronic treatment with aspirin and clopidogrel. The HPR was
defined as the upper quartile of maximal platelet aggregation (Aggmax) after 20 mol/l adenosine diphosphate
stimuli. Patients were followed up for 2 years and MACE were recorded.
Results A total of 41 MACE occurred in 34 patients (19.7%) during the 2-year follow-up. The MACE occurred in 15.2%, 12.2%,
12.2%, and 37.7% of patients from the lowest to upper quartile, respectively (p 0.005). The HPR was the strongest
independent predictor of MACE (hazard ratio 3.35, 95% confidence interval [CI] 1.68 to 6.66, p 0.001). Receiver-
operating characteristic analysis indicated that a cutoff value of 62% Aggmax best predicted MACE (37.8% vs. 13.2%,
odds ratio 3.96, 95% CI 1.8 to 8.7, p  0.001). Patients with HPR had up-regulation of multiple platelet signaling
pathways (p  0.0001 for all assays), indicative of a global hyperreactive platelet status.
Conclusions High platelet reactivity determined in T2DM patients with coronary artery disease while on chronic dual anti-
platelet therapy is associated with a higher risk of long-term adverse cardiovascular events, suggesting the need
for tailored antithrombotic drug regimens in these high-risk patients. (J Am Coll Cardiol 2007;50:1541–7)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.049(
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tigh platelet reactivity (HPR) has been associated with
hort- to mid-term atherothrombotic complications even in
atients taking combined aspirin and clopidogrel therapy
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ccepted May 28, 2007.1–5). However, most studies associating HPR with ad-
erse clinical outcomes were based on functional assess-
See page 1548
ents performed in the early phases of clopidogrel treat-
ent and/or in the context of patients undergoing percuta-
eous coronary intervention (1–5). A considerable number
f patients present with inadequate platelet inhibition early
fter initiation of dual antiplatelet therapy that improves
ith length of treatment (6,7). The clinical implications of
PR determined during a steady-state phase of dual anti-
latelet therapy warrants investigation.
High platelet reactivity is more frequent in patients with
ype 2 diabetes mellitus (T2DM) compared with nondia-
etic patients, even when treated with dual antiplatelet
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Platelet Reactivity and Outcomes in Diabetes October 16, 2007:1541–7therapy (8–10). Whether HPR
is associated with atherothrom-
botic complications in T2DM
patients remains to be investi-
gated. The goal of this study was
to assess platelet function profiles
selectively in T2DM patients
while in their chronic steady-
state phase of dual antiplatelet
therapy and evaluate the long-
term clinical implications of
HPR. We hypothesized that
HPR is associated with worse
long-term clinical outcomes in
2DM patients compared with those without HPR.
ethods
atient population and study design. Type 2 diabetes
ellitus patients with coronary artery disease (CAD) on
hronic treatment with dual antiplatelet therapy were eligi-
le for this study. Inclusion criteria for the study were: 1)
2DM on insulin or oral hypoglycemic medication; 2) age
etween 18 and 80 years; 3) history of CAD; and 4) use of
ual antiplatelet therapy for 6 to 9 months in the absence of
ardiovascular events during this period. Type 2 diabetes
ellitus was defined according to the World Health Orga-
ization report (11). All patients were recruited from the
utpatient clinic of our hospital in a consecutive manner and
ad previously undergone percutaneous coronary interven-
ion. Treatment with clopidogrel (75 mg/day) had been
rescribed for 12 months. Aspirin (100 mg/day) was used
ndefinitely.
At study entry, platelet function assessment was per-
ormed and patients were divided into 4 groups based on
uartile distribution of maximal 20 mol/l adenosine
iphosphate (ADP)-induced aggregation (Aggmax). Aden-
sine diphosphate was chosen as a platelet agonist for
efining the degree of post-treatment platelet reactivity as
atients were on dual antiplatelet therapy at the time of
lood sampling (1). The upper quartile of ADP-induced
latelet aggregation defined HPR (5). All patients were
aintained on clopidogrel for an additional 3 to 6 months
fter study entry and were prospectively followed up for 24
onths after platelet function assessment to determine the
ccurrence of adverse events. A flow diagram of the study
esign is shown in Figure 1.
Exclusion criteria for the study were as follows: 1)
mpaired glucose tolerance without pharmacologic treat-
ent, gestational diabetes, or transient hyperglycemia; 2)
llergy/intolerance to aspirin or clopidogrel; 3) concomitant
se of antithrombotic drugs other than aspirin and clopi-
ogrel (oral anticoagulants, dipyridamole, ticlopidine,
ilostazol) or nonsteroid anti-inflammatory drugs; 4) occur-
ence of an acute cardiovascular event during the interval
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
CAD  coronary artery
disease
HPR  high platelet
reactivity
MACE  major adverse
cardiovascular events
T2DM  type 2 diabetes
mellitusetween percutaneous coronary intervention and blood oampling; 5) platelet count 125,000/mm3; 6) hematocrit
25%; 7) creatinine levels 2.5 mg/dl; and 8) hepatic
isease (hepatic enzymes twice the upper normal limit).
This study complied with the Declaration of Helsinki
nd was approved by the Ethical Committee of the San
arlos University Hospital, and all patients gave their
nformed consent.
latelet function analysis. Blood samples for platelet
unction assays were collected from an antecubital vein using
21-gauge needle 2 to 4 h after antiplatelet therapy intake.
he first 2 to 4 ml of blood were discarded to avoid
pontaneous platelet activation. Platelet function measures
ncluded assessments of platelet aggregation and platelet
ctivation.
Platelet aggregation was assessed using light transmit-
ance aggregometry according to standard protocols as
reviously described (7–9,12). In brief, platelet aggregation
as assessed using platelet-rich plasma by the turbidimetric
ethod in a 2-channel aggregometer (ChronoLog 490
odel, ChronoLog Corp., Havertown, Pennsylvania) after
0-mol/l ADP stimuli. The platelet-rich plasma was
btained as a supernatant after centrifugation of citrated
lood at 800 rpm for 10 min. Platelet-poor plasma was
btained by a second centrifugation of the blood fraction at
,500 rpm for 10 min. The platelet count in platelet-rich
lasma was adjusted to the range of 250,000/l by dilution
ith autologous plasma when platelet count was out of
ange. Light transmission was adjusted to 0% with platelet-
ich plasma and to 100% for platelet-poor plasma for each
easurement. Curves were recorded for 6 min. Aggregation
as measured at peak (Aggmax) and at 5 min (Agglate) (12).
ercentage of platelet disaggregation (D) between Aggmax
nd Agglate values was defined as: D (%)  100  (1 
gglate/Aggmax) (12). In addition to stimuli with ADP,
Figure 1 Flow Diagram of the Studyther agonists nonspecific to the purinergic receptors were
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October 16, 2007:1541–7 Platelet Reactivity and Outcomes in Diabetessed to define platelet function profiles (10,14). These
ncluded collagen (6 g/ml), epinephrine (20 mol/l), and
hrombin receptor agonist peptide (25 mol/l) (9,13).
Platelet activation was determined by assessing platelet
urface expression of activated glycoprotein (GP) IIb/IIIa
nd P-selectin as previously described (7,8,14). The GP
Ib/IIIa activation was assessed using PAC-1 (PAC1-FITC
onjugated, Becton Dickinson, Rutherford, New Jersey) and
olyclonal fluorescein isothiocyanate-conjugated rabbit
nti-human fibrinogen (800 nM, Dako Diagnostics,
lostrup, Demmark) antibodies. P-selectin expression was
ssessed using a phycoerythrin-conjugated anti-CD62P (0.3
g/ml, Becton Dickinson, San José, California). An
pics-XL Profile II Coulter flow cytometer (Coulter Corp.
iami, Florida) was used for the assessment. Whole blood
as drawn into citrated tubes and diluted with N-2-
ydroxyethylpiperazine-N=-2-ethanesulfonic acid (HEPES)-
yrodes buffer to a final volume of 1:8:1 (blood to HEPES-
yrodes to citrate) resulting in a 1:10 dilution of whole blood
uring sampling. Then, 50 l of diluted whole blood was
timulated in vitro with 2-mol/l ADP (ChronoLog) before
mmunolabelling. The corresponding antibody was then added
nd incubated for 20 min. After incubation, samples were fixed
nd analyzed within 2 h. Acquisition and processing data were
nalyzed with XL2 software (Coulter Corp.). Platelet activa-
ion was expressed as the percentage of platelets positive for
ntibody binding.
linical end points and sample size calculation. Patients
ere followed up by telephone every 6 months and via
utpatient clinic visits on a yearly basis. Major adverse
ardiovascular events (MACE) were defined according to
efinitions proposed by the American College of Cardiol-
gy and included death secondary to cardiovascular cause,
T-segment elevation myocardial infarction (STEMI),
on–ST-segment elevation acute coronary syndrome (non–
T-segment elevation myocardial infarction [NSTEMI]
nd unstable angina [UA]), and stroke (15). Cardiovascular
eath was considered as any death with a demonstrable
ardiovascular cause or any death that was not clearly
ttributable to a noncardiovascular cause. The diagnosis of
TEMI was based on the evidence of new or presumably
ew ST-segment elevation in 2 consecutive leads and an
ncrease in biochemical markers of myocardial necrosis. The
iagnosis of NSTEMI was defined as the occurrence of
schemic symptoms, ST-segment depression and/or T-wave
bnormalities, and an increase of biochemical markers of
yocardial necrosis. The diagnosis of UA was defined as the
ccurrence of ischemic symptoms requiring hospitalization
ithout any biochemical evidence of myocardial necrosis.
troke was defined as the rapid onset of a new, persistent,
eurologic deficit lasting at least 24 h (or resulting in death
efore 24 h). The treating physicians and investigators who
valuated the clinical end points were blinded to the platelet
unction results.
The sample size was calculated assuming a 26% incidence
f MACE during the 2-year follow-up period. This esti-ation was based on previously published outcome data for
iabetic patients (16). We hypothesized a 3-fold increase in
he incidence of MACE in patients with HPR compared
ith patients with lower degrees of platelet reactivity. A
imilar magnitude of effect had been hypothesized in other
latelet function studies (4,17). A sample size of at least 150
atients would be needed to fulfill these assumptions with a
tatistical power of 0.90 to detect the hypothesized effect
ize with a 2-sided p value 0.05.
tatistical analysis. Continuous variables were analyzed
or a normal distribution with the Kolmogorov-Smirnov
est (using p value 0.2 as threshold). Continuous variables
ollowing a normal distribution are expressed as mean value
standard deviation; 1-way analysis of variance was used
or comparisons across quartiles and to generate p values for
rend tests. Variables not following a normal distribution are
xpressed as median (interquartile range); Kruskal-Wallis
nalysis of variance was used for comparisons across quar-
iles and to generate p values for trend tests. Categorical
ariables are expressed as frequencies and percentages.
omparisons of categorical variables were tested by the
hi-square test or Fisher exact test when at least 25% of
alues showed an expected cell frequency below 5. Survival
urves were constructed by the Kaplan-Meier method, and
vent-free survival among groups was compared using the
og-rank test. Cox proportional hazards regression analysis
as performed to identify independent correlates of the
ombined cardiovascular end point. The variables (demo-
raphic, clinical, and laboratory) entered in the hazards
egression model were selected using stepwise regression
nalysis with an entry criterion of p  0.10. Hazard ratio
HR) and 95% confidence intervals (CI) were calculated.
eceiver-operating characteristic (ROC) analysis was per-
ormed using MedCalc version 8.2.1.0 software (Mari-
Figure 2 Interindividual Distribution of Platelet Aggregation
Normal bell-shaped distribution of maximal adenosine diphosphate (ADP) (20
mol/l)-induced platelet aggregation in the overall diabetic population (n  173)
assessed at study entry (6 to 9 months after initiation of dual antiplatelet therapy).
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Platelet Reactivity and Outcomes in Diabetes October 16, 2007:1541–7kerke, Belgium) to define sensitivity and specificity of
latelet function testing. In addition, ROC analysis was
sed for an exploratory evaluation of the best cutoff point of
ggmax after ADP stimuli to predict MACE in our study
opulation; positive and negative predictive values also were
erived using this cutoff value. All probability values re-
orted are 2-sided, and a value of p  0.05 was considered
o be significant. Statistical analysis was performed using
PSS version 13.0 software (SPSS Inc., Chicago, Illinois).
esults
aseline characteristics. A total of 173 consecutive pa-
ients met the study inclusion criteria and were enrolled
rom January 2003 to February 2005. Overall, Aggmax after
DP stimuli was 52.0  14%, which was highly variable
nd followed a normal bell-shaped distribution (Fig. 2).
latelet reactivity quartile cut points for the 25th, 50th, and
5th percentiles of the study population were 44.0%, 52.0%,
nd 62.0%. The upper quartile defined HPR. The Aggmax
as 34.2  8%, 47.6  3%, 56.8  3%, and 68.6  6%,
rom the lowest to highest quartile, respectively (p 
.0001). Baseline demographics and clinical characteristics
aseline Demographic and Clinical Characteristics of the Entire Co
Table 1 Baseline Demographic and Clinical Characteristics of t
Entire Cohort
(n  173)
1st Quartile <44%
(n  41)
2nd
Age (yrs) 67 9 65 8
Male, n (%) 113 (65) 32 (78)
Caucasian, n (%) 173 (100) 41 (24)
BMI (30 kg/m2) 28.9 3.9 28.7 3.3
Risk factors/medical history, n (%)
Smoking 23 (13) 5 (12)
Hypertension 112 (65) 26 (63)
Dyslipidemia 118 (68) 3 (73)
Obesity (BMI 30 kg/m2) 65 (38) 13 (32)
Insulin-treated 54 (31) 8 (20)
Noninsulin treated 119 (69) 33 (80)
Prior MI 92 (53) 19 (46)
Prior stroke 7 (4) 3 (7)
Prior CABG 7 (4) 5 (12)
Symptomatic PAD 21 (12) 7 (17)
Multivessel CAD 127 (73) 34 (83)
Prior DES implantation 108 (62) 27 (66)
NYHA functional class III or IV 33 (19) 3 (7)
Chronic renal insufficiency* 36 (21) 2 (5)
Medical therapy, n (%)
Beta-blockers 120 (69) 32 (78)
ACE inhibitors 94 (54) 23 (56)
Nitrates 76 (44) 17 (42)
Lipid-lowering agents
CYP 3A4 pathway
metabolized
113 (65) 28 (68)
Non-CYP 3A4 pathway
metabolized
6 (4) 1 (2)
ata are expressed as mean SD or number of patients (%). *Chronic renal insufficiency is defin
ACE  angiotensin-converting enzyme; BMI  body mass index; CABG  coronary artery bypass gra
rug-eluting stent; MI  myocardial infarction; NYHA  New York Heart Association; PAD  peripheral af the study population as well as laboratory data are
escribed in Tables 1 and 2.
PR and clinical outcomes. Two-year clinical follow-up
as completed in all patients. A total of 41 MACE occurred
n 34 patients (19.6%) during the 2-year study follow-up
eriod; MACE occurred in 15.2%, 12.2%, 12.2%, and
7.7% of patients from the lowest to highest quartile,
espectively (p  0.005). The MACE event rates were
riven by UA/NSTEMI, which occurred in 9.8%, 10.9%,
2.2%, and 33.3% of patients from the lowest to highest
uartile, respectively (p 0.007). There were no differences
n the rates of the other individual cardiovascular events. Six
atients suffered more than 1 ischemic event. Four of these
atients had HPR; 1 patient with 3 events had HPR. A
otal of 3 patients died of noncardiac causes (first quartile, 1;
hird quartile, 1; fourth quartile, 1) due to lung cancer,
ost-traumatic cerebral hematoma, and spinal fracture.
Cumulative event-free survival from MACE was signif-
cantly lower in patients with HPR compared with other
roups (p  0.002) (Fig. 3). Patients with MACE had
igher Aggmax (56.8  13.8% vs. 50.9  13.6%, p  0.03)
han those with an uneventful follow-up. Multivariate Cox
egression analyses showed HPR (HR 3.35, 95% CI 1.68 to
and According to Quartiles of Platelet Aggregation
ntire Cohort and According to Quartiles of Platelet Aggregation
ile 44% to 52%
 46)
3rd Quartile 52% to 62%
(n  41)
4th Quartile >62%
(n  45) p Value
8 10 67 11 66 9 0.77
9 (63) 25 (61) 27 (60) 0.27
6 (26) 41 (24) 45 (26) 1.00
.9 4.3 29.2 3.8 28.9 4.3 0.97
6 (13) 5 (12) 7 (16) 0.96
2 (70) 25 (61) 29 (64) 0.86
9 (63) 28 (68) 31 (69) 0.79
7 (37) 17 (42) 18 (40) 0.81
6 (35) 13 (32) 17 (38) 0.28
0 (65) 28 (68) 28 (62) 0.28
3 (50) 26 (63) 24 (53) 0.44
1 (2) 2 (5) 1 (2) 0.57
0 (0) 1 (2) 1 (2) 0.02
6 (13) 4 (10) 4 (9) 0.65
1 (67) 26 (63) 36 (80) 0.31
7 (59) 24 (59) 30 (67) 0.78
2 (26) 8 (20) 10 (22) 0.14
3 (28) 10 (24) 11 (24) 0.04
8 (61) 32 (78) 28 (62) 0.13
0 (65) 21 (51) 20 (44) 0.24
0 (44) 18 (44) 21 (47) 0.97
6 (57) 25 (61) 34 (76) 0.24
1 (2) 2 (5) 2 (4) 0.86
reatinine clearance 60 ml/min.hort
he E
Quart
(n
6
2
4
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3
2
1
1
3
2
3
2
1
1
2
3
2
2
ed as c
ft surgery; CAD  coronary artery disease; CYP 3A4  hepatic cytochrome P450 3A4; DES 
rterial disease.
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October 16, 2007:1541–7 Platelet Reactivity and Outcomes in Diabetes.66, p  0.001), renal failure (HR 2.98, 95% CI 1.44 to
.17, p  0.003), and New York Heart Association func-
ional class III to IV (HR 2.87, 95% CI 1.38 to 5.98,
 0.005) to be independent predictors of MACE.
The ROC analysis indicated that a cutoff value of 62%
ggmax best predicted MACE in our study population. The
ACE rate was significantly higher in patients with plate-
et reactivity above compared with those below this cutoff
alue (37.7% vs. 13.3%, odds ratio [OR] 3.96, 95% CI 1.8
o 8.7, p  0.001). This measure of platelet function
howed a sensitivity and specificity of 46% and 84%,
espectively. The positive and negative predictive values of
2% Aggmax were 41% and 86%, respectively. Cumulative
vent-free survival from MACE using this cutoff value is
hown in Figure 4. The incidence of MACE was higher in
he HPR population both before (13.3% vs. 3.9%, p 0.03)
aboratory Data of the Entire Cohort and According to Quartiles of
Table 2 Laboratory Data of the Entire Cohort and According to
Entire Cohort
(n  173)
1st Quartile <44%
(n  41)
2nd Qua
Platelet count
(1,000/mm3)
220 47 207 52 2
Hematocrit (%) 40.1 3.9 41.2 3.9 4
MPV (fl) 8.8 1.1 8.8 1.1
HbA1C (%) 7.2 1.2 7.0 0.97
CRP (mg/dl) 0.31 [0.18–0.68] 0.30 [0.15–0.66] 0.31
Creatinine (g/dl) 1.07 0.28 1.01 0.19 1
Creatinine clearance
(ml/min)
75.9 21.7 80.4 16.9 7
ata are expressed as mean  SD or median [interquartile range].
CRP  C-reactive protein; HbA1C  glycated hemoglobin A1C; MPV  mean platelet volume.
Figure 3 Cumulative Event-Free Survival According
to Quartile Distribution of Platelet Aggregation
Cumulative event-free survival from cardiovascular events according to quartile
(Q) distribution of maximal adenosine diphosphate (20 mol/l)-induced platelet
aggregation.nd after (24.4% vs. 9.4%, p  0.01) clopidogrel with-
rawal.
latelet function profile analyses. Patients with HPR
howed abnormal platelet function in all parameters as-
essed. Patients with HPR had enhanced Agglate (24.7 
1.3%, 36.8  11.4%, 48.2  7.0%, 65.1  8.4% from first
o fourth quartile, respectively; p  0.0001) and diminished
latelet disaggregation (30.5  26.2%, 22.9  23.3%, 15.4
10.3%, 5.4  7.0% from first to fourth quartile, respec-
ively; p  0.0001) compared with patients in the lower
uartiles, indicative of a marked up-regulation of the P2Y12
athway. Platelet aggregation assessed using agonists non-
pecific to purinergic receptors (collagen, epinephrine, and
hrombin receptor agonist peptide) as well as markers of
latelet activation (P-selectin expression and GP IIb/IIIa
ctivation) also were all enhanced in patients with HPR
let Aggregation
tiles of Platelet Aggregation
4% to 52%
6)
3rd Quartile 52% to 62%
(n  41)
4th Quartile >62%
(n  45) p Value
43 219 44 233 54 0.09
3.8 40.0 3.7 39.0 3.9 0.08
1.3 8.9 1.0 8.8 0.9 0.73
0.92 7.1 1.1 7.5 1.5 0.09
–0.65] 0.33 [0.23–0.59] 0.30 [0.18–0.79] 0.93
0.28 1.07 0.26 1.11 0.36 0.47
18.6 78.2 24.3 73.5 25.4 0.27
Figure 4 Cumulative Event-Free Survival
According to Optimal ROC-Defined Cutoff Value
Cumulative event-free survival from cardiovascular events according to the opti-
mal receiver-operating characteristic (ROC)-defined cutoff value of 62% maximal
adenosine diphosphate (20 mol/l)-induced platelet aggregation (Agg ).Plate
Quar
rtile 4
(n  4
26
0.1
8.8
7.2
[0.15
.09
2.4max
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Platelet Reactivity and Outcomes in Diabetes October 16, 2007:1541–7Table 3). All platelet function parameters were significantly
igher in patients with platelet reactivity above the ROC-
etermined cutoff value as well (p  0.0001 for all assays).
iscussion
he present study shows the long-term prognostic impli-
ations of HPR, defined by ADP challenge, in T2DM
atients with CAD. In particular, patients with HPR
etermined in a steady-state phase of dual antiplatelet
herapy had an over 3-fold increase in 2-year cardiovascular
vent rates compared with those without HPR. Our data
lso suggest that multiple platelet signaling pathways in
ddition to those mediated by the purinergic receptors are
ighly up-regulated in patients with HPR, indicative of a
lobal hyperreactive platelet status.
Variability in individual response to dual antiplatelet
herapy is an emerging clinical entity (1,2). To date, studies
ssessing the prognostic implications of inadequate platelet
nhibition have been performed in patients undergoing
ercutaneous coronary interventions and/or in the initial
hase of dual antiplatelet treatment (1–5,17–20). Studies
ssessing outcomes in patients undergoing percutaneous
oronary interventions often are influenced by peri-
nterventional complications (1–5,17–20). Further, in the
nitial phase of dual antiplatelet therapy there are a higher
roportion of patients with inadequate platelet inhibition
6,7). Also, platelet function studies in the early phases of
ntiplatelet therapy often include patients with acute coro-
ary syndromes, who are more likely to have increased
latelet reactivity because of an increase in plasmatic levels
f von Willebrand factor (21). Overall, this enhances the
ikelihood of occurrence of adverse cardiovascular events.
ur study provides the first evidence on the long-term
rognostic value of HPR measured during a steady chronic
se of dual antiplatelet therapy without the confounding
ssociation of periprocedural complications or enhanced
latelet reactivity caused by an acute ischemic event.
The functional analyses performed in the present study
dentified a subset of patients with marked platelet hyper-
eactivity characterized by up-regulation of multiple platelet
latelet Function Profile Analyses
Table 3 Platelet Function Profile Analyses
Entire Cohort
(n  173)
1st Quartile <44%
(n  41)
2nd Qua
(
Platelet aggregation (%)
Collagen 42.4 18.5 25.6 14.4 38
Epinephrine 31.6 14.8 22.9 13.9 30
TRAP 68.2 13.6 57.9 15.3 66
Platelet activation (%)
Antifibrinogen 30.0 18.8 22.8 20.1 27
PAC-1 35.2 19.2 26.9 19.9 30
P-selectin 31.5 18.5 28.6 18.0 26
ata are expressed as mean  SD values of percentage of platelet aggregation or percentage of
TRAP  thrombin receptor agonist peptide.ignaling pathways beyond purinergic receptors. This is in pgreement with previous observations showing that subjects
ith hyperreactivity to one agonist tend to have a similar
esponse to others, suggesting that hyperreactivity is a global
haracteristic of platelets (22). This may explain why many
2DM patients with elevated post-treatment platelet reac-
ivity persist with enhanced platelet function even when
reated with a high maintenance dose of clopidogrel (12).
verall, these findings corroborate previous observations
uggesting that other pathways in addition to those stimu-
ated by purinergic receptors contribute to atherothrombotic
vents (3). Our previous observation (23) that patients with
ncreased platelet reactivity to nonpurinergic-specific ago-
ists have a greater augmentation of platelet function after
lopidogrel withdrawal may explain the enhanced absolute
isk of developing ischemic events after clopidogrel with-
rawal in patients with HPR. Whether these high-risk
atients will benefit from prolonged dual antiplatelet ther-
py, use of more potent drugs, or antiplatelet agents
nhibiting alternative targets (e.g., platelet protease-
ctivated receptors) remains to be investigated.
Patients with T2DM are at high risk for cardiovascular
vents (10) and are characterized by enhanced platelet
eactivity compared with nondiabetic patients (8,9). Sec-
ndary prevention measures for reduction of atherothrom-
otic events have been equally adopted for the overall
iabetic population. However, the present report shows that
2DM patients with HPR represent an even higher-risk
roup within the T2DM population, suggesting the need
or closer clinical monitoring in this subgroup. Although
ttractive, the concept of individualized antiplatelet treat-
ent regimens based on the degree of platelet reactivity,
imilar to current medical management of lipid and glucose
evels, remains to be tested (2,12). The major drawbacks in
ursuing such a therapeutic proposition are the lack of
tandardization of platelet function methods as well as
dentification of an optimal cutoff value (1,2).
Light transmittance aggregometry is considered the gold
tandard methodology for platelet function analysis (1), and
as used for defining the degree of post-treatment platelet
eactivity in this study. Patients in the lower 3 quartiles of
4% to 52%
6)
3rd Quartile 52% to 62%
(n  41)
4th Quartile >62%
(n  45) p Value
7.4 47.1 12.9 57.6 12.2 0.0001
5.3 34.2 12.7 38.3 12.8 0.0001
2.7 72.4 10.7 74.5 9.4 0.0001
8.4 29.9 14.9 39.2 17.9 0.0001
8.9 37.9 16.8 44.7 16.5 0.0001
8.6 28.9 17.4 41.3 16.5 0.0001
platelets.rtile 4
n  4
.5 1
.7 1
.8 1
.5 1
.8 1
.8 1latelet reactivity had similar outcomes, whereas MACE
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eems that, until a certain threshold is reached, an increase
n platelet reactivity is not paralleled by an enhanced risk of
ardiovascular events. Other studies support this observa-
ion (3,4,18). We found that 90% of patients with events
ad Aggmax 40%, whereas only 10% of patients without
vents had Aggmax 62%. The ROC analyses identified an
ggmax of 62% to best predict ischemic events in our
2DM population. This cut point had a good negative
redictive value, supporting that T2DM patients with
latelet reactivity below this threshold are at lower risk, with
n incidence of MACE of 13.3% over a period of 2 years.
hether these findings can be used to define therapeutic
oals to reduce the risk of ischemic events remains to be
nvestigated in prospective randomized studies. In addition,
he risk of bleeding with enhanced platelet inhibition must
e weighed against other potential clinical benefits.
tudy limitations. Single time point laboratory assess-
ents represent a common limitation to most studies
ssessing the prognostic implications of platelet function or
ther biological variables (1,24,25), including the present
eport. In addition, PAC-1 binding and fibrinogen binding
easured by flow cytometry used in this study may be
nfluenced by native fibrinogen binding to the activated GP
Ib/III receptor, and thus may not have the same value as
ncreased P-selectin expression (26). However, the numer-
us laboratory assays performed in our study may have
elped define more accurately the platelet function profiles
f our study population.
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